Department and Clinic of Internal Diseases, School of Public Health, Medical University of Silesia, Katowice, Poland.
Department of Molecular Biology, School of Pharmacy and the Division of Laboratory Medicine, Medical University of Silesia, Katowice, Poland.
Curr Pharm Biotechnol. 2019;20(7):551-561. doi: 10.2174/1389201020666190516090744.
Changes in expression of genes associated with proteins or organelles degradation system in the cell may be a cause or signal to carcinogenesis. Thus, the aim of this study was to assess the profile of gene expression linked to the degradation systems of proteins or organelles in histo-pathologically confirmed colorectal adenocarcinoma in relation to normal colon tissue.
Using oligonucleotide microarrays and GeneSpring 13.0, and PANTHER 13.1 software's we characterized 1095 mRNAs linked to the degradation system of proteins and organelles in sections of colorectal cancer from patients at various clinical stages of disease. Subsequent analyses with restrictive assumptions narrowed down the number of genes differentiating cancer, assuming a P-value of less than 0.05.
We found that most of the significant genes were silenced in the development of colorectal cancer. The FOXO1 had the lowest fold change value in the first clinical stage (CSI) comparing to the control. The HSPA8 was up-regulated in the two early clinical stages (CSI and CSII), and UBB only in the CSI. Only little-known PTPN22 showed increasing expression at all stages.
In summary, the examined colorectal adenocarcinoma samples were characterized by almost complete silencing of the significant genes associated with the degradation of proteins and mitochondria in transcriptomic level. The FOXO1, HSPA8 and UBB genes may become potential diagnostic and/or therapeutic targets in the early stage of this cancer.
细胞中与蛋白质或细胞器降解系统相关的基因表达的变化可能是致癌的原因或信号。因此,本研究旨在评估与组织病理学证实的结直肠腺癌相关的蛋白质或细胞器降解系统相关基因表达谱与正常结肠组织的关系。
使用寡核苷酸微阵列和 GeneSpring 13.0 以及 PANTHER 13.1 软件,我们对来自不同疾病临床阶段患者的结直肠癌组织中与蛋白质和细胞器降解系统相关的 1095 个 mRNA 进行了特征描述。随后的分析假设 P 值小于 0.05,对具有限制性假设的癌症分化基因进行了分析,从而缩小了基因的数量。
我们发现,大多数显著基因在结直肠癌的发展过程中被沉默。FOXO1 在第一临床阶段(CSI)与对照组相比,其折叠变化值最低。HSPA8 在两个早期临床阶段(CSI 和 CSII)上调,而 UBB 仅在 CSI 上调。只有鲜为人知的 PTPN22 在所有阶段都表现出表达增加。
综上所述,在转录组水平上,检查的结直肠腺癌样本的特征是与蛋白质和线粒体降解相关的显著基因几乎完全沉默。FOXO1、HSPA8 和 UBB 基因可能成为这种癌症早期诊断和/或治疗的潜在靶点。